AKUMS Q4 FY26 Results & Earnings Analysis
Sentiment: Neutral (Confidence: medium)
Earnings Summary
Akums reported a mixed FY26: a challenging H1 due to API price erosion and low domestic demand, but a strong H2 recovery driven by CDMO volume growth (+25%+ in H2) and record adjusted EBITDA (INR522 cr, +13.3% YoY). Q4 EBITDA margins improved to 13.1% (+420 bps YoY) on operating leverage. Key negatives: PAT declined to INR256 cr (vs INR344 cr) due to prior-year deferred tax benefit; API business continued losses (INR40 cr negative EBITDA); and no overall revenue guidance was provided. Positives: strong CDMO momentum, new contracts (Zambia $25M/year, European EUR200M), healthy cash position (INR1,682 cr), and expected sharp reduction in API losses. Management remains cautiously optimistic about FY27, with double-digit CDMO volume growth expected in H1 and margin expansion from new contracts in FY28. , , ,
Management Tone
- Prepared Remarks: Good — Prepared remarks highlighted a strong finish to FY26, record adjusted EBITDA, double-digit CDMO volume growth, progress in international markets (European GMP, Zambia), and a positive outlook for FY27 driven by CDMO, Zambia, and margin expansion in domestic branded and international branded segments
- Q&A Session: Neutral — The Q&A session was more cautious. Management confirmed double-digit volume growth visibility for H1 but refrained from giving full-year revenue guidance. They highlighted that the API business will remain loss-making for the full year, though losses will be 'sizably reduced.' The tone was measured
Revenue Growth Drivers
- Significant volume growth (25%+ in H2) from existing CDMO customers, driven by wallet share gains from in-house production shifts and other CDMOs.
- API price erosion (20-25% basket decline) negatively impacting CDMO absolute margins and API segment revenue.
- Pass-through model with percentage margins on input costs means absolute gross profit fluctuates with API prices.
Growth vs Margin Focus
Management emphasized organic growth (CDMO volume, new contracts, Zambia) while actively working on margin improvement through operating leverage, niche product mix, and cost rationalization in underperforming segments (trade generics, API). They also highlighted maintaining R&D investment for long-
About Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited (AKUMS) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.